Cagrilintide: A Revolutionary Peptide for Obesity and Metabolic Health
Hits: 541 Time: 2025.11.17
Cagrilintide emerges as a groundbreaking investigational peptide reshaping obesity and type 2 diabetes management, leveraging a dual-action mechanism to address metabolic health at its core. As a long-acting amylin analog, it mimics the body’s natural amylin hormone while activating GLP-1 receptors, creating a synergistic approach to appetite regulation and glucose control .
Its scientific design sets it apart: an acylated modification extends its half-life to 7-8 days, enabling convenient once-weekly subcutaneous administration— a key advantage for patient adherence . By slowing gastric emptying and enhancing satiety signals in the hypothalamus, cagrilintide reduces caloric intake while stabilizing blood sugar through glucose-dependent insulin secretion, minimizing hypoglycemia risks . Clinical trials confirm its efficacy: doses of 0.3-4.5 mg deliver 6.0%-10.8% weight loss over 26 weeks, with the 4.5 mg dose outperforming traditional therapies .
Beyond standalone use, cagrilintide shines in combination therapy (CagriSema) with semaglutide, amplifying weight loss to 17.1% in early trials—surpassing single-agent treatments . It’s also being studied for chronic kidney disease linked to obesity and diabetes, expanding its therapeutic reach . Well-tolerated with mild gastrointestinal side effects, cagrilintide represents a safe, targeted solution for the global metabolic health crisis .
As clinical development advances, cagrilintide stands poised to redefine standards for weight management and metabolic disorder treatment, offering hope for sustainable health improvements.
Wan Chai District, Hong Kong, China
